1stOncology™: Cancer Intelligence Service – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026

On October 14, 2026 Likang Life Sciences reported it will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will join a panel discussion titled "The Future of Cancer" on October 21 to explore advances in precision oncology and the translation of innovative cancer treatments into clinical practice.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Convened by the Department of Health – Abu Dhabi (DoH), the summit brings together policymakers, researchers, clinicians, investors, and industry leaders from around the world. Under the theme "To Sense Is to Predict," the event focuses on artificial intelligence, genomics, advanced diagnostics, and the future of personalized healthcare. Organizers expect participants from approximately 100 countries and more than 175 exhibiting organizations.

As part of the summit’s Abu Dhabi Blueprints series, "The Future of Cancer" panel will examine advances in cancer care and the roles of research, investment, policy, and international collaboration in bringing innovative therapies to patients.

Likang Life Sciences is developing personalized cancer immunotherapies through its proprietary AI-powered neoantigen discovery platform, which identifies and prioritizes patient-specific tumor neoantigens. The platform supports a pipeline spanning personalized therapeutic cancer vaccines and neoantigen-specific T-cell therapies.

Its lead investigational candidate, LK101, is a personalized neoantigen mRNA-DC therapeutic cancer vaccine. LK101 received clinical trial authorization from China’s National Medical Products Administration (NMPA) in 2023 and U.S. FDA Investigational New Drug (IND) clearance in 2025.

At the summit, Likang Life Sciences will highlight its technology platform, clinical development programs, and experience in advancing personalized immunotherapies from research into clinical development. The company also looks forward to engaging with international healthcare institutions, researchers, and industry partners, particularly within Abu Dhabi’s growing precision medicine ecosystem, to explore opportunities for scientific and clinical collaboration.

Through its participation, Likang Life Sciences aims to strengthen international scientific and clinical collaboration, accelerate the development of personalized cancer immunotherapies, and contribute to the advancement of precision oncology worldwide.

(Press release, Likang Life Sciences, OCT 14, 2026, View Source [SID1234673362])

Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate

On October 14, 2026 Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), reported that the first patient has been dosed in a Phase 1 clinical trial evaluating ORM-1153, the Company’s investigational CD123-GSPT1 DAC, in patients with relapsed or refractory acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.

ORM-1153 combines Orum’s internally developed CD123-targeting antibody with a proprietary GSPT1 degrader payload. The antibody was engineered for efficient internalization into target cells and reduced Fc-gamma receptor interactions, with a linker designed for plasma stability. Preclinical studies demonstrated activity across primary AML patient samples and models with TP53 mutations, providing a rationale for evaluating ORM-1153 in patients with difficult-to-treat disease.

"We have built a substantial preclinical data package for ORM-1153, and our task now is to establish how those findings translate clinically," said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. "The preparation of our team and the support of our clinical site partners enabled us to move efficiently from IND clearance through site activation to dosing. The study will allow us to assess whether the improvements in payload delivery observed preclinically translate into a favorable balance of activity and tolerability in patients."

"Patients with relapsed or refractory AML, particularly those with high-risk molecular features, continue to have poor outcomes and need additional treatment options," said Andrew Sochacki, M.D,. Associate Director of Hematology at START Midwest. "Targeted delivery of a GSPT1 degrader offers a different approach to treating these cancers. This Phase 1 study will provide important initial information about ORM-1153’s safety, pharmacology, and potential activity in patients."

The first-in-human Phase 1 study is an open-label, dose-escalation trial designed to identify the optimal biological dose and evaluate the safety and tolerability of ORM-1153. The study will also characterize its pharmacokinetic and pharmacodynamic profile and assess preliminary antileukemic activity. Approximately 42 patients are expected to be enrolled at multiple clinical sites initially in the United States, potentially followed by sites in other regions. Additional information is available on ClinicalTrials.gov under identifier NCT07809906.

About ORM-1153

ORM-1153 is a CD123-GSPT1 degrader-antibody conjugate developed using Orum’s proprietary GSPT1 degrader platform. The molecule combines a proprietary GSPT1-degrading payload with an internally developed anti-CD123 antibody engineered for high internalization efficiency through a cleavable β-glucuronide linker. Following internalization and payload release, ORM-1153 is designed to induce cancer cell death through targeted degradation of GSPT1. In preclinical studies presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, ORM-1153 demonstrated activity across primary AML patient samples and TP53-relevant models, along with antileukemic activity at low doses in vivo. Its safety and efficacy in patients have not been established.

(Press release, Orum Therapeutics, OCT 14, 2026, View Source [SID1234673356])

Novastra Therapeutics to Present Initial Phase 1 Data for OAP-101 in Anti–PD-1–Refractory Advanced Melanoma at ESMO Congress 2026

On October 13, 2026 Novastra Therapeutics, a clinical-stage biotechnology company developing a novel category of cancer immune therapy, reported that initial clinical data from an ongoing investigator-initiated Phase 1 study of its candidate OAP-101 in anti-PD-1-refractory advanced melanoma will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

Novastra’s OmniAntigen Platform (OAP) enables systematic immune reprogramming therapy (XIRT), with off-the-shelf in situ and autologous approaches designed to coordinate tumor-antigen presentation with innate immune activation, priming tumor-directed immunity. These approaches aim to overcome resistance of cold solid tumors to checkpoint inhibition and to act as an immune amplification companion for antibody-drug conjugates (ADCs), chemotherapy, and radiotherapy.

Presentation details:
Presentation type: Poster
Session: Investigational Immunotherapy
Title: OAP-101 autologous whole-tumor antigen system-level immune reprogramming therapy in anti–PD-1–refractory advanced melanoma
Presenting author: Junling Guo, PhD, Chief Executive Officer, Novastra Therapeutics
Presentation number: 2000P
Date and time: Saturday, October 24, 2026, at 12:00 – 12:45 CEST

The poster will feature the first clinical data for Novastra’s OAP/XIRT approach in a setting designed to overcome checkpoint-inhibitor resistance in immunologically cold solid tumors. The Phase 1 study investigates OAP-101 in patients with advanced metastatic melanoma refractory to multiple lines of currently available therapy, including anti-PD-1 checkpoint inhibition.

The full abstract will be available as of 12:05 a.m. CEST on October 19, 2026, through the ESMO (Free ESMO Whitepaper) Congress 2026 online programme and the Annals of Oncology Abstract Book supplement.

Reaching more patients with cold solid tumors who are currently left behind
Despite advances in checkpoint inhibition and ADCs, many patients with solid tumors still experience treatment resistance. For immunotherapy, a key challenge is the absence of an effective anti-tumor immune response because the tumor hides from immune recognition.1-3

Built on OAP, XIRT is designed to overcome this challenge by priming the immune system. OAP enables rapid antigen encapsulation with a supramolecular nanocloak for effective presentation to the immune system. The nanocloak is designed to combine antigen delivery with innate immune stimulation, including activation of the cGAS-STING pathway, connecting the innate and adaptive immune systems.4 OAP enables the preservation of a broad repertoire of tumor-cell antigens in autologous settings. For in vivo applications, Novastra is designing an in-situ approach where the nanocloak self-assembles within the tumor, capturing tumor-derived antigens released by ADCs, chemotherapy, or radiotherapy.

(Press release, Novastra Therapeutics, OCT 13, 2026, View Source [SID1234673377])

Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update

On October 13, 2026 Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, reported it will publish its financial results for the third quarter of 2026 on Thursday, 5 November 2026.

In connection with the third quarter results, the Company will provide an update on its activities during the quarter, including progress in the ongoing Phase 1 ZIMA-101 study of ZI-MA4-1, Zelluna’s first-in-class MAGE-A4-targeting TCR-NK cell therapy for advanced solid tumours.

The presentation will be available via a live webcast on www.zelluna.com at 09:00 CET on Thursday, 5 November 2026, and participants will be able to submit questions during the presentation. The webcast recording will remain available on the Company’s website after the event.

The quarterly report and presentation materials will be published on the Company’s website at 07:00 CET on Thursday, 5 November 2026, ahead of the webcast.

(Press release, Zelluna Immunotherapy, OCT 13, 2026, View Source [SID1234673376])

Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

On October 13, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers reported that it has enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. The trial, branded "Serenta" is recruiting at 29 clinical sites across the US and five countries in Europe with a further two sites in Canada expected to be initiated shortly.

The Serenta protocol provides for a pre-specified futility analysis after 25 Progression Free Survival (PFS) events and database lock after 75 PFS events in the Serenta trial. The Serenta protocol includes a composite endpoint which defines the nature of the PFS events.

Commenting, Stephen Stamp, Chief Executive Officer of Biodexa said "Enrolment of the 100th patient represents an important milestone for Serenta and reflects the continued strong recruitment performance across our participating sites. Based on the current rate of PFS event accrual, the pre-specified futility analysis could take place early next year with database lock potentially occurring around the end of next year, both significantly sooner than originally anticipated".

About Familial Adenomatous Polyposis

FAP is characterized by the proliferation of polyps in the colon, duodenum and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. If untreated, FAP typically leads to colorectal cancer. There is a significant hereditary component to FAP with a reported incidence of one in 5,000 to 10,000 in the US and one in 11,300 to 37,600 in Europe. eRapa has received Orphan Drug Designation in the US and in Europe. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and generally safe mTOR inhibitor like eRapa to treat FAP.

About eRapa
eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Data from an open label Phase 2 trial were presented at Digestive Disease Week and InSIGHT 2024 in May and June 2024, respectively. Based on those data, Biodexa initiated a double-blind, placebo-controlled Phase 3 registrational trial in the US and Europe and plans to enrol 168 subjects randomized 2:1, drug: placebo. The Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.

(Press release, Biodexa Pharmaceuticals, OCT 13, 2026, View Source [SID1234673375])